Initial results from a real-world study of the ProVue Lung test demonstrate 83% sensitivity for Stage I cancer in high-risk patients.
PrognomiQ announced early results for its ProVue Lung blood-based laboratory-developed test, showing high sensitivity for detecting lung cancer in high-risk individuals, according to a company release. The test detected early-stage disease with 83% sensitivity in an ongoing real-world study.
In a cohort of 78 high-risk adults, the test accurately identified eight lung cancers, five of which were provisionally categorized as Stage I. All cases were confirmed by tissue biopsy. The results showed an overall sensitivity of 89% across all stages at 54% specificity.
Participants in the study were adults aged 50 and older with a smoking history of at least 20 pack-years, consistent with current US Preventive Services Task Force screening guidelines. The findings were generated through an Early Experience Program launched in November 2025 with Penn Highlands Healthcare and Allegheny Health Network.
“High-performance detection of stage I lung cancers provides the most clinical utility, and it is promising to see a blood-based test identifying cancers at this earliest stage in our patients,” says Sandeep Bansal, medical director of the Lung Center and Interventional Pulmonology at Penn Highlands Healthcare, in a release.
The test is designed to complement low-dose CT (LDCT) scanning, which currently faces barriers to adoption. According to the company, fewer than 16% of the 14 million people eligible for LDCT screening in the US actually undergo the procedure.
“These exciting initial findings support the idea that a blood-based test like ProVue Lung could help expand access and bring more patients into screening pathways for early detection, particularly for early-stage disease,” says Ali Zaidi, medical director of lung and esophageal research at Allegheny Health Network, in a release.
The ProVue Lung test utilizes a proteomic signature to identify cancer. Philip Ma, CEO of PrognomiQ, notes that the ability to identify cancers amenable to curative therapies reinforces the potential for proteomics in clinical settings.
“These results show breakthrough and unprecedented performance, and the consistent performance of our assay across cohorts of increasing statistical rigor helps validate our technical differentiation and robust approach to product design,” says Ma in a release.
The Early Experience Program is ongoing, with plans to expand to additional health systems in the coming months. PrognomiQ intends to present further clinical data at future scientific conferences and in peer-reviewed publications.
ID 119090223 © Angellodeco | Dreamstime.com
